Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biological activity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    555 result(s) found for: Biological activity. Displaying page 9 of 28.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2022-000837-17 Sponsor Protocol Number: NL80854.018.22 Start Date*: 2022-12-07
    Sponsor Name:Amsterdam UMC
    Full Title: Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study
    Medical condition: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001301-42 Sponsor Protocol Number: 111473 Start Date*: 2009-01-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase II study to assess the clinical activity and safety of recMAGE-A3 + AS15 cancer immunotherapeutic in patients with metastatic cutaneous melanoma, and to explore its immunogenic proper...
    Medical condition: Adult patients with histologically proven, measurable metastatic cutaneous melanoma (stage III in transit or unresectable, or stage IV M1a), with documented progressive disease within the 12 weeks ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002262-39 Sponsor Protocol Number: 131I-IPA-TLX-101-001 Start Date*: 2018-10-24
    Sponsor Name:TELIX International Pty Ltd
    Full Title: A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I...
    Medical condition: 2nd line therapy of recurrent GBM (Glioblastoma multiforme), scheduled for repeat XRT.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004892-21 Sponsor Protocol Number: IP-004 Start Date*: 2008-04-08
    Sponsor Name:IMMUPHARMA SA
    Full Title: Estudio Fase IIb, Multicéntrico, Aleatorizado, Doble-Ciego, Controlado con Placebo de Búsqueda de dosis, para Evaluar Eficacia, Seguridad y Tolerabilidad de Dos Dosis Subcutáneas de IPP-201101 Más ...
    Medical condition: Lupus Eritematoso Sistémico (LES)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006812-10 Sponsor Protocol Number: BBI-20201001 Start Date*: 2023-04-05
    Sponsor Name:Bolt Biotherapeutics, Inc.
    Full Title: Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors.
    Medical condition: Advanced HER2-Expressing Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10075638 HER2 protein overexpression PT
    23.0 10010331 - Congenital, familial and genetic disorders 10075653 HER2 gene amplification PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000672-42 Sponsor Protocol Number: BIA-STD-003 Start Date*: 2012-10-11
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them.
    Medical condition: Treatment and diagnosis of allergy to Artemisa vulgaris, Platanus acerifolia and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    14.1 10021428 - Immune system disorders 10066092 Acaridae allergy LLT
    14.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002431-53 Sponsor Protocol Number: IB2021-03 Start Date*: 2022-09-23
    Sponsor Name:Institut Bergonié
    Full Title: A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000488-17 Sponsor Protocol Number: LUPIL-2 Start Date*: 2016-08-08
    Sponsor Name:ILTOO PHARMA
    Full Title: A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ILT-101 in patients with active moderate to severe systemic lup...
    Medical condition: Systematic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) ES (Completed) BG (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000665-32 Sponsor Protocol Number: 80202135SJS2001 Start Date*: 2021-11-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10040766 Sjogren's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) PT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002206-52 Sponsor Protocol Number: CD-ON-MEDI4736-1108 Start Date*: 2012-12-05
    Sponsor Name:MedImmune
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020738-24 Sponsor Protocol Number: Version 1.2 (20/06/2011) Start Date*: 2010-10-12
    Sponsor Name:King's College London
    Full Title: Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA)
    Medical condition: Patients with established Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002051-42 Sponsor Protocol Number: R119861 Start Date*: 2019-10-25
    Sponsor Name:University of Manchester
    Full Title: A phase I-II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11b lentiviral vector encoding for human SGSH in patients with mucopolysaccharidosis type IIIA (MPS IIIA,...
    Medical condition: MPS IIIA, mucopolysaccharidosis type IIIA
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028093 Mucopolysaccharidosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000923-32 Sponsor Protocol Number: OSM104972 Start Date*: 2008-08-13
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016537-98 Sponsor Protocol Number: SRT-2104-011 Start Date*: 2010-02-22
    Sponsor Name:Sirtris Pharmaceuticals Inc.
    Full Title: A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability and Activity of Oral SRT2104 Capsules Administered for 28 days to Subjects with Type 2 Di...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004163-39 Sponsor Protocol Number: OV126b Start Date*: 2017-06-30
    Sponsor Name:ARCAGY-GINECO
    Full Title: A randomized, open-label, multicentric phase II trial of PEMBROLIZUMAB (Ketruda®) with chemotherapy versus chemotherapy alone (standard of care) as neo adjuvant treatment of ovarian cancer not amen...
    Medical condition: advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001273-23 Sponsor Protocol Number: 2021NanoLi-CT01 Start Date*: 2021-09-20
    Sponsor Name:MEDESIS PHARMA SA
    Full Title: A prospective, multicenter, with a first part randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period trial to evaluate the clinical safety and ef...
    Medical condition: Sufficient clinical and paraclinical information for the diagnosis of Alzheimer’s Disease (AD) according to the international diagnosis criteria from McKhann G. M. et al. 2011
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002052-21 Sponsor Protocol Number: NCT03804723 Start Date*: 2022-06-21
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: TARGETing steroid withdrawal in SLE (TARGET2020 STUDY): a randomized, phase IV, open -label, non-inferiority trial
    Medical condition: Systemic Lupus Eritematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10042944 Systemic lupus erythematosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000093-11 Sponsor Protocol Number: 205218 Start Date*: 2017-02-08
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Athe Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningo...
    Medical condition: Healthy volunteers (Infections, Meningococcal)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002614-36 Sponsor Protocol Number: 05ICHF/T407 Start Date*: 2007-04-20
    Sponsor Name:IBSA
    Full Title: Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomi...
    Medical condition: Substitutive and/or TSH suppressive therapy in thyroidectomized patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021117 Hypothyroidism postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005208-26 Sponsor Protocol Number: P13/12 Start Date*: 2016-02-22
    Sponsor Name:Centre Hospitalier de Versailles
    Full Title: CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVIN...
    Medical condition: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10058246 Chronic myelogenous leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 03:51:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA